Currently released so far... 97115 / 251,287
Articles
Brazil
Sri Lanka
United Kingdom
Sweden
00. Editorial
United States
Latin America
Egypt
Jordan
Yemen
Thailand
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/09
2011/05/10
2011/05/11
2011/05/12
2011/05/13
2011/05/14
2011/05/15
2011/05/16
2011/05/17
2011/05/18
2011/05/19
2011/05/20
2011/05/21
2011/05/22
2011/05/23
2011/05/24
2011/05/25
2011/05/26
2011/05/27
2011/05/28
2011/05/29
2011/05/30
2011/05/31
2011/06/01
2011/06/02
2011/06/03
2011/06/04
2011/06/05
2011/06/06
2011/06/07
2011/06/08
2011/06/09
2011/06/10
2011/06/11
2011/06/12
2011/06/13
2011/06/14
2011/06/15
2011/06/16
2011/06/17
2011/06/18
2011/06/19
2011/06/20
2011/06/21
2011/06/22
2011/06/23
2011/06/24
2011/06/25
2011/06/26
2011/06/27
2011/06/28
2011/06/29
2011/06/30
2011/07/01
2011/07/02
2011/07/04
2011/07/05
2011/07/06
2011/07/07
2011/07/08
2011/07/10
2011/07/11
2011/07/12
2011/07/13
2011/07/14
2011/07/15
2011/07/16
2011/07/17
2011/07/18
2011/07/19
2011/07/20
2011/07/21
2011/07/22
2011/07/23
2011/07/25
2011/07/27
2011/07/28
2011/07/29
2011/07/31
2011/08/01
2011/08/02
2011/08/03
2011/08/05
2011/08/06
2011/08/07
2011/08/08
2011/08/10
2011/08/11
2011/08/12
2011/08/13
2011/08/15
2011/08/16
2011/08/17
2011/08/19
2011/08/21
2011/08/22
2011/08/23
2011/08/24
2011/08/25
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Antananarivo
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Alexandria
Consulate Adana
American Institute Taiwan, Taipei
Embasy Bonn
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Brazzaville
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangui
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Belfast
Consulate Barcelona
Embassy Cotonou
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chiang Mai
Consulate Chennai
Consulate Chengdu
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
DIR FSINFATC
Consulate Dusseldorf
Consulate Durban
Consulate Dubai
Consulate Dhahran
Embassy Guatemala
Embassy Grenada
Embassy Georgetown
Embassy Gaborone
Consulate Guayaquil
Consulate Guangzhou
Consulate Guadalajara
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Hong Kong
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kolonia
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Krakow
Consulate Kolkata
Consulate Karachi
Consulate Kaduna
Embassy Luxembourg
Embassy Lusaka
Embassy Luanda
Embassy London
Embassy Lome
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy Libreville
Embassy La Paz
Consulate Leipzig
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Mission Geneva
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Mogadishu
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maseru
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Merida
Consulate Melbourne
Consulate Matamoros
Consulate Marseille
Embassy Nouakchott
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Nuevo Laredo
Consulate Naples
Consulate Naha
Consulate Nagoya
Embassy Pristina
Embassy Pretoria
Embassy Praia
Embassy Prague
Embassy Port Of Spain
Embassy Port Moresby
Embassy Port Louis
Embassy Port Au Prince
Embassy Podgorica
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Ponta Delgada
Consulate Peshawar
REO Mosul
REO Kirkuk
REO Hillah
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Surabaya
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy Tirana
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
Consulate Thessaloniki
USUN New York
USMISSION USTR GENEVA
USEU Brussels
US Office Almaty
US Mission Geneva
US Mission CD Geneva
US Interests Section Havana
US Delegation, Secretary
US Delegation FEST TWO
UNVIE
UN Rome
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vientiane
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
AF
ADANA
ASEC
AFIN
AMGT
AE
AORC
AID
AR
AO
AU
ASEAN
AGOA
AFGHANISTAN
AFFAIRS
AMED
APER
ASECARP
APEC
AEMR
AS
AA
ANET
AFLU
ABLD
AL
ASUP
AJ
APECO
AMER
ABUD
AODE
AM
AFSN
AESC
AND
AG
ALOW
AROC
AVIANFLU
ATRN
ACOA
AEGR
AMGMT
AADP
AFSI
ACABQ
APRM
AZ
AIDS
ASE
AGAO
ADCO
ABDALLAH
ARF
AIDAC
ACOTA
ASCH
AC
ASEG
AGR
ACS
AMCHAMS
AN
AMIA
ASIG
ADPM
ADB
ANARCHISTS
ALOWAR
ARM
AUC
AINF
AINT
AORG
AY
AVIAN
AMEDCASCKFLO
AK
ARSO
ARABBL
ASO
ANTITERRORISM
ARABL
AOWC
AGRICULTURE
ALJAZEERA
AMTC
AFINM
AOCR
ABER
ARR
AFPK
ASSEMBLY
ASSK
AZE
AORCYM
AINR
AGMT
AEC
ACKM
APRC
AIN
ASCC
AFPREL
ASED
APERTH
ASFC
ASECTH
AFSA
AOMS
AORCO
ANTXON
ARC
AFAF
ADIP
AIAG
AFARI
AEMED
AORL
AX
ASECAF
AOPC
ASECAFIN
AFZAL
APCS
AMB
AGUIRRE
AEMRASECCASCKFLOMARRPRELPINRAMGTJMXL
AIT
ARCH
AMEX
ALI
AQ
ATFN
AMBASSADOR
AORCD
AVIATION
ARAS
AINFCY
ACBAQ
AOPR
AREP
ALEXANDER
ATRD
AEIR
AOIC
ABLDG
ASEX
AFR
ASCE
ATRA
ASEK
AER
ALOUNI
AMCT
AVERY
APR
AMAT
AEMRS
ASPA
AFU
AMG
ATPDEA
ALL
AECL
ACAO
ASECKFRDCVISKIRFPHUMSMIGEG
AORD
AFL
AME
ADM
ASECPHUM
AGIT
ABT
ASECVE
AGUILAR
AT
ABMC
ALZUGUREN
ANGEL
ASR
ANTONIO
BMGT
BEXP
BM
BG
BL
BA
BR
BTA
BO
BY
BBSR
BLUE
BK
BF
BTIO
BELLVIEW
BE
BU
BN
BH
BD
BC
BTC
BILAT
BT
BX
BRUSSELS
BP
BB
BRPA
BUSH
BURMA
BMENA
BESP
BIT
BBG
BGD
BMEAID
BAGHDAD
BEN
BIO
BMOT
BWC
BLUNT
BURNS
BUT
BGMT
BAIO
BCW
BOEHNER
BFIF
BOL
BASHAR
BIMSTEC
BOU
BIDEN
BZ
BFIN
BTRA
BI
BHUM
BOIKO
BERARDUCCI
BOUCHAIB
BORDER
BEXPC
BTIU
BTT
BIOS
BEXB
BGPGOV
BOND
BLR
CE
CG
CH
CVR
CASC
CU
CI
CD
CO
CDG
CB
CJAN
CPAS
COM
CVIS
CMGT
CT
CENTCOM
CNARC
CTERR
COUNTER
CHIEF
CDC
CTR
CBW
COUNTRY
CLEARANCE
CY
CA
CM
CS
CWC
CN
CITES
CF
CWG
CIVS
CFIS
CASCC
CROATIA
CONS
COUNTERTERRORISM
CASA
COE
CJ
CHR
CODEL
CR
CBC
CACS
CHERTOFF
CAS
CONTROL
CONDITIONS
CONDOLEEZZA
CITEL
CV
CLINTON
CHG
CZ
CON
CTBT
CEN
CRIMES
COMMERCE
CLOK
CRISTINA
CFED
CARC
CND
CTM
CARICOM
COUNTRYCLEARANCE
CBTH
CHINA
CSW
CICTE
CJUS
CYPRUS
CW
CAMBODIA
CENSUS
CIDA
CRIME
CBG
CBE
CMGMT
CAIO
CEC
CARSON
CPCTC
CEDAW
COMESA
CVIA
CWCM
CEA
COSI
CAPC
CGEN
COPUOS
CGOPRC
COETRD
CKGR
CFE
CQ
CITT
CIC
CARIB
CVIC
CLO
CAFTA
CVISU
CHRISTOPHER
CACM
CIAT
CDB
CIS
CUL
CHAO
CNC
CL
CSEP
COMMAND
CENTER
COL
CAN
CAJC
CUIS
CONSULAR
CLMT
CIA
CBSA
CEUDA
CAC
CROS
CIO
CPUOS
CKOR
CVPR
CONG
CONTROLS
CEPTER
CVISCMGTCASCKOCIASECPHUMSMIGKIRF
CDCE
DPOL
DEMARCHE
DHS
DR
DA
DISENGAGEMENT
DEMOCRATIC
DEFENSE
DJ
DY
DARFUR
DHRF
DEA
DTRO
DPRK
DO
DARFR
DOC
DRL
DK
DOJ
DTRA
DOMESTIC
DAC
DOD
DEAX
DIEZ
DEOC
DELTAVIOLENCE
DCOM
DMINE
DRC
DCG
DPKO
DOMESTICPOLITICS
DE
DB
DOT
DEPT
DOE
DHLAKAMA
DHSX
DS
DKEM
DAO
DCM
DANIEL
DEM
DAVID
DCRM
ETRD
EAGR
ETTC
EAID
ECON
EFIN
ECIN
EINV
ELAB
EAIR
ENRG
EPET
EWWT
ECPS
EIND
EMIN
ELTN
EC
ETMIN
EUC
EZ
ET
ELECTIONS
ENVR
EU
EUN
EG
EINT
ER
ECONOMICS
ES
EMS
ENIV
EEB
EN
ECE
ECOSOC
EK
ENVIRONMENT
EFIS
EI
EWT
ENGRD
ECPSN
EXIM
EIAD
ERIN
ECPC
EDEV
ENGY
ECTRD
EPA
ESTH
ECCT
EINVECON
ENGR
ERTD
EUR
EAP
EWWC
ELTD
EL
EXIMOPIC
EXTERNAL
ETRDEC
ESCAP
ECO
EGAD
ELNT
ECONOMIC
ENV
ETRN
EIAR
EUMEM
ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID
EREL
ECOM
ECONETRDEAGRJA
ETCC
ETRG
ECONOMY
EMED
ETR
ENERG
EITC
EFINOECD
EURM
EENG
ERA
EXPORT
ENRD
ECONEINVETRDEFINELABETRDKTDBPGOVOPIC
EGEN
EBRD
EVIN
ETRAD
ECOWAS
EFTA
ECONETRDBESPAR
EGOVSY
EPIN
EID
ECONENRG
EDRC
ESENV
ETT
EB
ENER
ELTNSNAR
ECHEVARRIA
ETRC
EPIT
EDUC
ESA
EFI
ENRGY
ESCI
EE
EAIDXMXAXBXFFR
EETC
ECIP
EIAID
EIVN
EBEXP
ESTN
EING
EGOV
ETRA
EPETEIND
ELAN
ETRDGK
EAIDRW
ETRDEINVECINPGOVCS
EPEC
ENVI
ELN
EAG
EPCS
EPRT
EPTED
ETRB
EUM
EAIDS
EFIC
EFINECONEAIDUNGAGM
EAIDAR
ESF
EIDN
ELAM
EDU
EV
EAIDAF
ECN
EDA
EXBS
EINTECPS
ENRGTRGYETRDBEXPBTIOSZ
EPREL
EAC
EINVEFIN
ETA
EAGER
EINDIR
ECA
ECLAC
ELAP
EITI
EUCOM
ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID
EARG
ELDIN
EINVKSCA
ENNP
EFINECONCS
EFINTS
ECCP
ETC
EAIRASECCASCID
EINN
ETRP
EAIDNI
EFQ
ECOQKPKO
EGPHUM
EBUD
ECONEINVEFINPGOVIZ
ENERGY
ELB
EINDETRD
EMI
ECONEFIN
EIB
EURN
ETRDEINVTINTCS
EIN
EFIM
ETIO
ELAINE
EMN
EATO
EWTR
EIPR
EINVETC
ETTD
ETDR
EIQ
ECONCS
EPPD
ENRGIZ
EISL
ESPINOSA
ELEC
EAIG
ESLCO
EUREM
ENTG
ERD
EINVECONSENVCSJA
EEPET
EUNCH
ECINECONCS
ETRO
ETRDECONWTOCS
ECUN
EFND
EPECO
EAIRECONRP
ERGR
ETRDPGOV
ECPN
ENRGMO
EPWR
EET
EAIS
EAGRE
EDUARDO
EAGRRP
EAIDPHUMPRELUG
EICN
ECONQH
EVN
EGHG
ELBR
EINF
EAIDHO
EENV
ETEX
ERNG
ED
FR
FREEDOM
FINREF
FJ
FI
FRELIMO
FOREIGN
FAA
FETHI
FAS
FTAA
FRB
FAO
FCS
FINANCE
FWS
FTA
FEMA
FDA
FLU
FRANCISCO
FBI
FORCE
FO
FARC
FK
FT
FCSC
FAC
FM
FMGT
FINV
FCSCEG
FARM
FERNANDO
FINR
FIN
FINE
FIR
FDIC
FOR
FOI
FCUL
FKLU
FMLN
FISO
FIXED
GM
GMUS
GG
GR
GE
GAZA
GT
GH
GZ
GJ
GLOBAL
GV
GABY
GOI
GA
GCC
GB
GY
GATT
GC
GUAM
GEORGE
GTIP
GOV
GOMEZ
GUTIERREZ
GL
GKGIC
GF
GU
GWI
GARCIA
GTMO
GN
GANGS
GIPNC
GAERC
GREGG
GUILLERMO
GASPAR
GERARD
GI
HK
HR
HUMANR
HUMAN
HO
HA
HUMANRIGHTS
HU
HHS
HIV
HUM
HRKAWC
HILLEN
HILLARY
HDP
HUMRIT
HSTC
HUMANITARIAN
HCOPIL
HADLEY
HURI
HL
HRETRD
HOURANI
HG
HARRIET
HESHAM
HI
HNCHR
HARRY
HRECON
HRC
HOSTAGES
HEBRON
HUMOR
HSWG
HYMPSK
HECTOR
HN
HYDE
HUD
HRPGOV
HIGHLIGHTS
ID
ILC
IS
IZ
ICAO
IMO
ITU
IR
IAEA
ICRC
IPROP
IT
IBRD
ISRAELI
IRAQI
ISSUES
ITRA
IV
IO
IGAD
IRAQ
IN
IMF
ICTR
ISCON
IADB
IDB
IEA
INR
IWC
ICCAT
ILO
INMARSAT
IOM
ICJ
IQ
ISPA
ITRD
IPR
INTELSAT
ISN
IAHRC
INTERNAL
IFAD
IICA
IHO
IRAN
IL
IRCE
IC
INTELLECTUAL
IRM
IE
ICTY
IDLI
IFO
ISCA
INF
INL
ISRAEL
INV
IBB
INFLUENZA
ISPL
ITER
ITIA
INRA
ISAF
IACHR
INTERPOL
IFR
IRS
INRB
IEF
ISAAC
ICC
INDO
IIP
IATTC
INAUGURATION
IND
INS
IZPREL
IACI
IEFIN
INNP
ILAB
IA
IMTS
ITALY
ITALIAN
IFIN
IRAJ
IX
ICG
IF
ITPHUM
ITA
IP
IACW
IK
IUCN
IZEAID
IRPE
IDA
ISLAMISTS
ITF
INRO
IBET
IDP
IRC
ISO
ICES
IRMO
ITPGOV
IQNV
IMSO
IRDB
IMET
INCB
IFRC
JA
JO
JP
JM
JCIC
JOHN
JE
JEFFERY
JS
JUS
JN
JOHNNIE
JAMES
JKUS
JOSEPH
JML
JAWAD
JSRP
JIMENEZ
JOSE
JKJUS
JK
JAPAN
KMDR
KPAO
KPKO
KJUS
KCRM
KGHG
KFRD
KWMN
KDEM
KTFN
KHIV
KGIC
KIDE
KSCA
KNNP
KHUM
KIPR
KSUM
KISL
KIRF
KCOR
KRCM
KPAL
KWBG
KN
KS
KOMC
KSEP
KFLU
KPWR
KTIA
KSEO
KMPI
KHLS
KICC
KSTH
KMCA
KVPR
KPRM
KE
KU
KZ
KFLO
KSAF
KTIP
KTEX
KBCT
KOCI
KOLY
KOR
KAWC
KACT
KUNR
KTDB
KSTC
KLIG
KSKN
KNN
KCFE
KCIP
KGHA
KHDP
KPOW
KUNC
KDRL
KV
KPREL
KCRS
KPOL
KRVC
KRIM
KGIT
KWIR
KT
KIRC
KOMO
KRFD
KUWAIT
KG
KFIN
KSCI
KTFIN
KFTN
KGOV
KPRV
KSAC
KGIV
KCRIM
KPIR
KSOC
KBIO
KW
KGLB
KMWN
KPO
KFSC
KSEAO
KSTCPL
KSI
KPRP
KREC
KFPC
KUNH
KCSA
KMRS
KNDP
KR
KICCPUR
KPPAO
KCSY
KTBT
KCIS
KNEP
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KNNB
KGCC
KINR
KPOP
KMFO
KENV
KNAR
KVIR
KDRG
KDMR
KFCE
KNAO
KDEN
KGCN
KICA
KIMMITT
KMCC
KLFU
KMSG
KSEC
KUM
KCUL
KMNP
KSMT
KCOM
KOMCSG
KSPR
KPMI
KRAD
KIND
KCRP
KAUST
KWAWC
KTER
KCHG
KRDP
KPAS
KITA
KTSC
KPAOPREL
KWGB
KIRP
KJUST
KMIG
KLAB
KTFR
KSEI
KSTT
KAPO
KSTS
KLSO
KWNN
KPOA
KHSA
KNPP
KPAONZ
KBTS
KWWW
KY
KJRE
KPAOKMDRKE
KCRCM
KSCS
KWMNCI
KESO
KWUN
KPLS
KIIP
KEDEM
KPAOY
KRIF
KGICKS
KREF
KTRD
KFRDSOCIRO
KTAO
KJU
KWMNPHUMPRELKPAOZW
KEN
KO
KNEI
KEMR
KKIV
KEAI
KWAC
KRCIM
KWCI
KFIU
KWIC
KCORR
KOMS
KNNO
KPAI
KBWG
KTTB
KTBD
KTIALG
KILS
KFEM
KTDM
KESS
KNUC
KPA
KOMCCO
KCEM
KRCS
KWBGSY
KNPPIS
KNNPMNUC
KWN
KERG
KLTN
KALM
KCCP
KSUMPHUM
KREL
KGH
KLIP
KTLA
KAWK
KWMM
KVRP
KVRC
KAID
KSLG
KDEMK
KX
KIF
KNPR
KCFC
KFTFN
KTFM
KPDD
KCERS
KMOC
KDEMAF
KMEPI
KEMS
KDRM
KEPREL
KBTR
KEDU
KNP
KIRL
KNNR
KMPT
KISLPINR
KTPN
KA
KJUSTH
KPIN
KDEV
KTDD
KAKA
KFRP
KWNM
KTSD
KINL
KJUSKUNR
KWWMN
KECF
KWBC
KPRO
KVBL
KOM
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KEDM
KFLD
KLPM
KRGY
KNNF
KICR
KIFR
KM
KWMNCS
KAWS
KLAP
KPAK
KDDG
KCGC
KID
KNSD
KMPF
KPFO
KDP
KCMR
KRMS
KNPT
KNNNP
KTIAPARM
KDTB
KNUP
KPGOV
KNAP
KNNC
KUK
KSRE
KREISLER
KIVP
KQ
KTIAEUN
KPALAOIS
KRM
KISLAO
KWM
KFLOA
LE
LU
LH
LA
LG
LO
LY
LANTERN
LI
LABOR
LORAN
LTTE
LT
LAS
LAB
LAW
LVPR
LARREA
LEBIK
LAURA
LS
LOTT
LOVE
LR
LEON
LAVIN
LGAT
LV
LAOS
LOG
LN
LB
MOPS
MO
MARR
ML
MASS
MZ
MR
MNUC
MX
MV
MCC
MY
MEDIA
MTCRE
MG
MCAP
MOPPS
MP
MI
MK
MC
MD
MA
MU
MASC
MW
MT
MEPP
MN
MTCR
MH
MEPI
MIL
MNUCPTEREZ
MMAR
MICHAEL
MUNC
MDC
MPOS
MONUC
MAR
MGMT
MAS
MEPN
MENDIETA
MARIA
MONTENEGRO
MOOPS
MSG
MARITIME
MURRAY
MUKASEY
MOTO
MCA
MFO
MEX
MRSEC
MMED
MACP
MAAR
MINUSTAH
MCCONNELL
MAPP
MGT
MARQUEZ
MANUEL
MNUR
MCCAIN
MF
MOHAMMAD
MOHAMED
MNU
MFA
MILITANTS
MINORITIES
MTS
MLS
MILI
MIAH
MEETINGS
MERCOSUR
MED
MARAD
MNVC
MINURSO
MNUCUN
MIK
MARK
MBM
MPP
MILITARY
MAPS
MNUK
MILA
MTRRE
MACEDONIA
MICHEL
MASSMNUC
MUCN
MQADHAFI
MPS
MARRGH
MRCRE
MTRE
MORALES
MAP
MCTRE
MHUC
MOPSGRPARM
MOROCCO
MCAPS
NL
NU
NS
NI
NPT
NATO
NO
NG
NATEU
NSF
NZ
NAS
NP
NDP
NLD
NGO
NEPAD
NAFTA
NASA
NEA
NGUYEN
NIH
NK
NIPP
NONE
NR
NANCY
NEGROPONTE
NRR
NERG
NSSP
NSG
NSFO
NE
NATSIOS
NFSO
NATIONAL
NTDB
NT
NCD
NTSB
NRC
NELSON
NAM
NH
NPG
NEC
NSC
NFATC
NMFS
NATOIRAQ
NAR
NZUS
NARC
NCCC
NA
NC
NEW
NRG
NUIN
NOVO
NATOPREL
NEY
NV
NICHOLAS
NPA
NW
NARCOTICS
NORAD
NOAA
NON
NTTC
NKNNP
NMNUC
NUMBERING
ODIP
OIIP
OPRC
OSCE
OREP
OTRA
OPET
OSCI
OVIP
OECD
OCII
OUALI
OPDC
OEXC
OFPD
OPIC
OFDP
OPCW
OECV
OAS
OM
OMIG
ODAG
OPREP
ORA
OIC
OEXCSCULKPAO
OIG
OASS
OFFICIALS
ORTA
OSAC
OIL
OIE
OEXP
OPEC
OPDAT
OMS
OES
OHI
OMAR
OCRA
OFSO
OCBD
OSTA
OAO
ONA
OTP
ORC
OAU
OXEC
OA
ODPC
OPDP
OVIPPRELUNGANU
OASC
OSHA
OPCD
OTR
OPPI
OPCR
OF
OFDPQIS
OSIC
OHUM
OSTRA
OASCC
OBSP
OFDA
OPICEAGR
OIM
OGAC
OTA
OTRAORP
OPPC
OESC
OCEA
OVP
ON
OPAD
OTAR
OCS
ODC
OTRD
OCED
OSD
ORUE
OREG
PHUM
PINR
PTER
PGOV
PREL
PREF
PL
PM
PHSA
PE
PARM
PINS
PK
PUNE
PO
PALESTINIAN
PU
PBTS
PROP
PTBS
POL
POLI
PA
PGOVZI
POLMIL
POLITICAL
PARTIES
POLM
PD
POLITICS
POLICY
PAS
PMIL
PINT
PNAT
PV
PKO
PPOL
PERSONS
PING
PBIO
PH
PETR
PARMS
PRES
PCON
PETERS
PRELBR
PT
PLAB
PP
PAK
PDEM
PKPA
PSOCI
PF
PLO
PTERM
PJUS
PSOE
PELOSI
PROPERTY
PGOVPREL
PARP
PRL
PNIR
PHUMKPAL
PG
PREZ
PGIC
PBOV
PAO
PKK
PROV
PHSAK
PHUMPREL
PROTECTION
PGOVBL
PSI
PRELPK
PGOVENRG
PUM
PRELKPKO
PATTY
PSOC
PRIVATIZATION
PRELSP
PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ
PMIG
PREC
PAIGH
PROG
PSHA
PARK
PETER
POG
PHUS
PPREL
PS
PTERPREL
PRELPGOV
POV
PKPO
PGOVECON
POUS
PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN
PWBG
PMAR
PREM
PAR
PNR
PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO
PARMIR
PGOVGM
PHUH
PARTM
PN
PRE
PTE
PY
POLUN
PPEL
PDOV
PGOVSOCI
PIRF
PGOVPM
PBST
PRELEVU
PGOR
PBTSRU
PRM
PRELKPAOIZ
PGVO
PERL
PGOC
PAGR
PMIN
PHUMR
PVIP
PPD
PGV
PRAM
PINL
PKPAL
PTERE
PGOF
PINO
PHAS
PODC
PRHUM
PHUMA
PREO
PPA
PEPFAR
PGO
PRGOV
PAC
PRESL
PORG
PKFK
PEPR
PRELP
PREFA
PNG
PGOVPHUMKPAO
PRELECON
PINOCHET
PFOR
PGOVLO
PHUMBA
PRELC
PREK
PHUME
PHJM
POLINT
PGOVPZ
PGOVKCRM
PGOVE
PHALANAGE
PARTY
PECON
PEACE
PROCESS
PLN
PRELSW
PAHO
PEDRO
PRELA
PASS
PPAO
PGPV
PNUM
PCUL
PGGV
PSA
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGIV
PRFE
POGOV
PEL
PBT
PAMQ
PINF
PSEPC
POSTS
PHUMPGOV
PVOV
PHSAPREL
PROLIFERATION
PENA
PRELTBIOBA
PIN
PRELL
PGOVPTER
PHAM
PHYTRP
PTEL
PTERPGOV
PHARM
PROTESTS
PRELAF
PKBL
PRELKPAO
PKNP
PARMP
PHUML
PFOV
PERM
PUOS
PRELGOV
PHUMPTER
PARAGRAPH
PERURENA
PBTSEWWT
PCI
PETROL
PINSO
PINSCE
PQL
PEREZ
PBS
RS
REFUGEES
RW
RP
RELFREE
RO
REGIONAL
RIGHTS
REACTION
REPORT
RU
RENAMO
RIGHTSPOLMIL
REFORM
RM
REFUGEE
REL
RELATIONS
ROW
RREL
REGION
RATIFICATION
RBI
RICE
ROOD
RODENAS
RUIZ
RODHAM
ROBERT
RGY
ROY
REUBEN
RELIGIOUS
RUEHZO
RODRIGUEZ
RUEUN
RELAM
RSP
RF
RSO
RCMP
REO
ROSS
RPTS
RENE
REID
RUPREL
RMA
RI
REMON
RPEL
RFE
RFIN
RA
RAFAEL
RAY
RUS
RPREL
ROBERTG
RECIN
RAMONTEIJELO
SNAR
SP
SN
SMIG
SL
SOCI
SU
SG
SF
SENV
SZ
SOE
SCUL
SY
SO
SR
SYR
SE
SA
SW
SIPDIS
SCIENCE
SADC
SI
SCI
SOCIETY
SC
SAARC
STR
SECRETARY
SANC
SSH
ST
SNA
SGWI
SEP
SOCIS
SETTLEMENTS
SPECIALIST
SK
SHUM
START
STET
SCVL
SREF
SCHUL
SCUIL
SYRIA
SECURITY
SPCE
SYAI
SMIL
SOWGC
STEPHEN
SNRV
SKCA
SENSITIVE
SECI
SNAP
SPP
SCUD
SOM
SPECI
SMIGBG
SENC
SCRM
SGNV
SECTOR
SENVEAGREAIDTBIOECONSOCIXR
SENVSXE
SASIAIN
SACU
SENVSPL
SWMN
STEINBERG
SOPN
SOCR
SCOI
SCRS
SILVASANDE
SWE
SARS
SNARIZ
SUDAN
SENVQGR
SM
SNARKTFN
SAAD
SD
SAN
SIPRNET
STATE
SENS
SUBJECT
SFNV
SECSTATE
SSA
SPCVIS
SOI
SOFA
SCULKPAOECONTU
SPTER
SKSAF
SENVKGHG
SHI
SEVN
SANR
SPSTATE
SMITH
SCOM
SH
SNARCS
SNARN
SIPRS
SNARM
SIPDI
SCPR
SNIG
SELAB
SULLIVAN
SENVENV
SECDEF
SOLIC
SOIC
SPAS
SASC
SOSI
SEC
SEN
SENVCASCEAIDID
TU
TH
TW
TSPA
TRGY
TPHY
TBIO
TIFA
TS
TZ
TX
TSPL
TT
TK
TC
TINT
TERFIN
TERRORISM
TIP
TURKEY
TI
TECHNOLOGY
TNGD
TRSY
TRAFFICKING
TOPEC
TPSL
TP
TD
TR
TA
TIO
TREATY
TO
THPY
TECH
TRADE
TPSA
TG
TAGS
TF
TRAD
THKSJA
TVBIO
TNDG
TN
TBIOZK
TWI
TV
TWL
TRT
TWRO
TSRY
TTPGOV
TAUSCHER
TRBY
TRBIO
TL
TPKO
TIA
TGRY
TSPAM
TREL
TNAR
TBI
TFIN
TPHYPA
TWCH
THOMMA
THOMAS
TERROR
TRY
TBID
TPP
TE
THANH
TJ
TBKIO
UNGA
USUN
UN
UG
UNSC
UK
UP
US
UNCTAD
UNVIE
UNHRC
USTR
UNAMA
UNCRIME
UNESCO
UV
UNDP
UNHCR
UNCSD
UNCHR
UZ
USAID
UNEP
UNO
UNPUOS
UY
UNDC
UNCITRAL
UNAUS
UNCND
UA
UNMIK
USTDA
USEU
USDA
UNICEF
UR
UNFICYP
USNC
USTRRP
UNODC
UNRWA
UNOMIG
USTRPS
USAU
USCC
UNEF
UNGAPL
UNFPA
UNSCE
USSC
UGA
UEU
UNMIC
UNTAC
UNION
UNCLASSIFIED
USPS
UNA
UMIK
USOAS
UNMOVIC
UNFA
UNAIDS
UNCHC
USGS
UNSE
UNRCR
UNTERR
USG
UE
UAE
UNWRA
UNCSW
UNSCR
UNCHS
UNDESCO
UNPAR
UNC
UB
UNSCS
UKXG
UNGACG
UNREST
UNHR
USPTO
UNFCYP
USCG
UNIDROIT
UNSCD
UPU
UNBRO
UNECE
USTRUWR
UNCC
UNESCOSCULPRELPHUMKPALCUIRXFVEKV
VM
VE
VT
VETTING
VN
VZ
VIS
VC
VTPREL
VIP
VTEAID
VTEG
VOA
VA
VTIZ
VANG
VISIT
VO
VENZ
VAT
VI
VEPREL
VEN
WFP
WTO
WHO
WTRO
WBG
WMO
WIPO
WA
WI
WSIS
WHA
WCL
WE
WMN
WEBZ
WS
WAR
WZ
WMD
WW
WILLIAM
WEET
WAEMU
WM
WWBG
WWT
WWARD
WITH
WMDT
WTRQ
WCO
WEU
WALTER
WRTO
WB
WHTI
WBEG
WCI
WEF
WAKI
WHOA
WGC
Browse by classification
Community resources
courage is contagious
Viewing cable 05BANGKOK7526, PHARMACEUTICAL COSTS AND THE FTA
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #05BANGKOK7526.
| Reference ID | Created | Released | Classification | Origin |
|---|---|---|---|---|
| 05BANGKOK7526 | 2005-12-07 09:54 | 2011-08-25 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Bangkok |
This record is a partial extract of the original cable. The full text of the original cable is not available.
070954Z Dec 05
UNCLAS SECTION 01 OF 06 BANGKOK 007526
SIPDIS
SENSITIVE
DEPARTMENT PASS USTR FOR BWEISEL, VESPINEL
GENEVA FOR USTR
COMMERCE FOR ITA/MAC/AP/OKSA/JBENDER AND JKELLY
HHS FOR OGHA STEIGER, ELVANDER AND BHAT
USPTO FOR DKEATING AND MMOEZIE
E.O. 12958: N/A
TAGS: ECON ETRD KIPR TH
SUBJECT: PHARMACEUTICAL COSTS AND THE FTA
¶1. (U) Summary and Introduction: The prospect of strong
"TRIPS-plus" patent provisions in a U.S.-Thailand Free Trade
Agreement (FTA) has been a controversial issue in Thailand.
Anti-FTA activists from NGOs and within the RTG claim that
stronger patent protection for pharmaceutical products in an
FTA with the U.S. would prevent or delay the production of
cheaper generic drugs to compete with pharmaceutical imports.
They fear the FTA would raise overall health costs and
prevent access to cheap essential medicines desperately
needed in a developing nation with scarce resources to fund
large-scale health programs, particularly for HIV/AIDS
treatment.
¶2. (U) The immediate effect of the FTA on pharmaceutical
costs in Thailand would appear to be low. Although the
patent system and market exclusivity it provides to
pharmaceutical companies has kept the prices of some drugs
high, there are few drugs currently on the market whose costs
would be further affected by the patent provisions likely to
be included in an FTA. Delays in patent and marketing
approval that could add extra life to patent terms under an
FTA are few and manageable with additional resources.
Thailand has a capable generic pharmaceutical industry that
can copy most any drug, but the likelihood is low that the
RTG would break the patent on any given drug and produce it
generically, despite frequent demands by FTA critics.
¶3. (U) This cable aims to examine the potential effects of
an FTA on pharmaceutical costs in Thailand. Although a
patent chapter has yet to be introduced by either side in FTA
negotiations, previous U.S. FTAs with other nations give some
indication as to what patent provisions could look like in a
U.S.-Thai FTA. End Summary and Introduction.
Pharma in a nutshell
--------------------
¶4. (U) According to industry analysts, the pharmaceutical
industry in Thailand had revenues of over USD 1.4 billion in
2004 and has been growing an average of 12 percent over the
last five years. Approximately 3000 pharmaceutical products
are on the market in Thailand, both original products and
generic copies. Multinational firms control approximately 60
percent of market share, though two Thai firms break the list
of top ten largest firms, Siam Pharmaceuticals and the
state-owned Government Pharmaceutical Organization which
almost exclusively produce generic products. An estimated 25
percent of pharmaceutical imports came from U.S.-based
companies in 2004, but given the global nature of most
pharmaceutical companies, teasing out what percentage of
imports was produced in which country is difficult to
accomplish. U.S.-based pharmaceutical giant Pfizer is the
industry leader in Thailand; Merck and Bristol-Myers Squibb
make the top ten as well.
What's the problem?
-------------------
¶5. (U) Health care activists in a number of Thai and
international NGOs claim that increased patent and data
protection for pharmaceutical products resulting from an FTA
with the U.S. could delay the introduction of cheaper generic
competitors. As drug expenditures account for approximately
30 percent of total health care expenditure in Thailand,
there is great concern for availability of cheap medicines to
stretch the Thai health care budget. A recent and somewhat
alarmist study by the Ministry of Public Health predicted
that an FTA could raise annual health care costs by as much
as USD five billion. Although even NGO activists admitted
that number was wildly unrealistic, Thai FTA negotiators have
cited the figure as a reason for concern in negotiations with
the U.S. on IPR.
¶6. (U) Despite the range of products on the market in
Thailand (and the range of maladies), concern with the FTA
and pharmaceuticals has focused almost exclusively on
HIV/AIDS medicines and the impact of an FTA on treatment for
the large number of patients in Thailand. Despite a
successful campaign in the 1990s to slow the spread of AIDS,
approximately 570,000 Thais are HIV positive. The World Bank
estimated that nearly 50,000 Thais died from AIDS in 2004,
though the death rate has been decreasing as treatment
improves and becomes more widespread. The Bank estimated
nearly 20,000 new cases of HIV occurred in 2004.
¶7. (U) The RTG Ministry of Public Health (MoPH) has
allocated 2.7 billion Baht (USD 66 million) for
implementation of an anti-retroviral treatment scheme for
FY2006. MOPH has set a goal to provide free treatment to
80,000 HIV positive patients under the universal health care
scheme. Health officials say that although there are 570,000
HIV positive cases in Thailand, only 100-120,000 have reached
the stage of the disease where treatment is necessary, making
the MoPH goal close to near universal treatment for patients
who require it.
¶8. (U) Thailand's Government Pharmaceutical Organization
(GPO) makes its own generic antiretroviral cocktail, GPO-vir,
a cocktail of three anti-retrovirals (ARVs) which are off
patent. Approximately 70,000 of the patients to be treated
under MoPH's program will receive GPO-vir at a cost to the
RTG of only a dollar a day per patient. However, drug
resistance to GPO-vir has increased over the past two years
and an additional 10,000 patients in the MoPH program require
second-line ARVs to continue treatment. The few second-line
ARV cocktails available include drugs patented in Thailand by
multinational pharmaceutical companies, and are available
only at up to ten times the cost of first-line regimens. As
more AIDS patients build resistance to the first-line ARVs,
the number of patients needing more expensive second-line
treatment will only increase.
Patent term restoration, or unnecessary extension?
--------------------------------------------- -----
¶9. (U) FTA critics point to provisions in recent U.S. FTAs
that affect pharmaceutical products and could restrict access
to essential medicines in Thailand. Recent U.S. FTAs include
articles that require governments to lengthen the term of a
patent to compensate the patent holder for any unreasonable
delays in the issuance of the patent or during the marketing
approval process. The pharmaceutical industry considers this
just compensation for opportunity lost to sell their product
with market exclusivity. FTA critics call it an unwarranted
extension of the 20-year patent term, and fear that it will
delay the introduction of cheaper generic competitors.
¶10. (U) FTA patent provisions would unlikely have an
immediate effect on drug patent terms. At present, few
pharmaceuticals are under patent in Thailand as the RTG only
recently began accepting pharmaceutical patent applications
in September, 1992. Owing to the sometimes decade-long
process of creation of a new drug, many if not most of the
chemical compounds which have been submitted for patent
approval in Thailand have yet to reach market.
¶11. (SBU) A U.S.-Thai FTA would also not appear to have any
immediate effect on availability or price of ARVs in
Thailand. At present, only four of the 13 ARVs on Thailand's
National List of Essential Drugs (NLED) are under patent.
GPO already makes generic copies of most unpatented ARVs on
the NLED and would presumably continue to do so post-FTA.
There are other ARVs not on the NLED that are patented as
well, but industry analysts knew of none (on or off the NLED)
that would receive patent term extension from an FTA.
¶12. (SBU) Despite patent protection and the market
exclusivity that it allows, pharmaceutical companies in
Thailand claim they do not charge excessive monopoly prices
on their products. Most companies practice price
differentiation, selling their products at a steep discount
from what they would charge in the U.S. in recognition of the
different level of income in Thailand. In addition, despite
the patent, companies still face competition from other
products which, while not precisely the same, have similar
purposes. Thailand is a respectably-sized market and there
is ample presence of most major multinational pharmaceutical
companies, not to mention a domestic generic industry that
competes strongly in off-patent products. Nevertheless, one
company estimated the price dropped an average of 40 percent
after the end of a drug's patent protection.
Unreasonable delays in patent and market approval?
--------------------------------------------- -----
¶13. (U) The pharmaceutical industry complains of excessive
delays in awarding patents and cites an average of five years
to approve a patent on a pharmaceutical product. Mr. Suradet
Atsawintarangkun, head of the biotechnology section of the
Thai Patent Office (TPO), insisted that his section processed
most applications for new chemical compounds within one or
two years, five years at the outside. Econoff toured the TPO
where five patent examiners specialized in pharmaceutical and
biotech products. Desks were piled high with some of the
estimated 100 new applications received monthly, most inches
thick with detailed scientific data on the new chemical
compounds.
¶14. (U) One point on which nearly everyone agrees is that
the TPO is strained for resources. TPO's Suradet said patent
applications were increasingly complicated and hi-tech and
examiners were pressed to thoroughly check data in patent
applications. Most examiners in the biotech section were
graduates of Masters-level science programs, but Suradet
admitted that the TPO found it difficult to compete with the
private sector for the best graduates. Examiners tended to
rely heavily on patent approval reports by the U.S. Patent &
Trademark Office, but nevertheless made their own
determinations. Applications from foreign firms were
difficult as well because technical experts from the firms
were not nearby to answer technical questions. The lengthy
process of sending examiners' questions from TPO through a
series of lawyers to the patent applicant and finally back
again added further delays.
¶15. (U) Delays in issuance of patents are not a primary
concern of the pharmaceutical industry in Thailand as the
patent is typically examined and approved while companies are
still engaged in the lengthy research and development of a
new drug. However, drug companies are concerned with
uncertainty in the process and great variation in the length
of time required for a patent to be approved. Although some
drugs take many years to produce, others are ready for market
relatively quickly.
¶16. (U) The industry is more concerned for potential delays
in the market approval process, as at this stage a new drug
is ready for marketing and delays mean lost revenue.
However, in contrast to their grumblings about the TPO, the
pharmaceutical industry had few complaints about market
approval. The Thai Food and Drug Administration (TFDA) has
responsibility for determining the quality, safety and
efficacy of new drugs before allowing them on the market.
The TFDA gives itself 180 working days to approve a new drug,
though the clock stops if additional information is required
from the submitting company. Most approvals are issued in an
acceptable 12-18 month range, though the TFDA can process an
application much more quickly for life-saving drugs it would
like to speed to market.
Data exclusivity ) protecting secret data or blocking out
generics?
--------------------------------------------
¶17. (U) Data exclusivity provisions in a proposed FTA have
also been controversial. Typical provisions in an FTA
require governments to protect clinical test data submitted
in support of marketing approval for five years after product
approval, not only from disclosure to other parties, but also
to essentially prevent generic manufacturers from relying on
test data submitted by other companies to support
applications for market approval for their own generic
copies, regardless of whether the product was ever patented.
¶18. (U) Current Thai law under the Trade Secrets Act
provides for protection for clinical test data, though
implementing regulations have yet to be approved. TFDA keeps
test data under lock and key and there have been no
complaints of leaks of confidential data. However, there are
no restrictions on generic firms from relying on test data
from the original producers when submitting generic copies
for approval. Although the generic firms never see the data,
the TFDA will accept an application for market approval for a
generic drug shown to be bioequivalent to the original drug
and accept that the drug has already been proven to be safe
and effective based on earlier approval with the original
test data.
¶19. (U) Protection of clinical test data is a high priority
for the pharmaceutical industry as a majority of their
products were never patented in Thailand, either because of
the unavailability of patents before 1992 or simply because
the market was not considered important enough to warrant the
cost of the patent filing. Pharmaceutical companies claim
that the costs of product development and clinical testing of
new drugs can run into the hundreds of millions and call for
data exclusivity to protect that investment. Generic drug
firms in Thailand currently have a significant competitive
advantage in foregoing expensive and lengthy testing of their
own to produce a generic copy, but these firms and the RTG
question the logic of forcing generic producers to needlessly
undertake the same clinical tests that the original producer
had already completed years before. They claim the end
result would be delays in the introduction of cheaper
generics, even for products that were never patented.
¶20. (U) The Thai pharmaceutical industry association, Prema,
believes only a handful of drugs (none of them ARVs) would
receive immediate benefit from an FTA regarding data
exclusivity. As data exclusivity is typically granted for
only five years, an FTA would affect only those drugs that
came on the market in the previous five years. Approximately
30 new innovative drugs come on the Thai market every year,
meaning an estimated 150 drugs could benefit from data
exclusivity at any given time after an FTA entered into
force. However, the increasing prevalence of patent filings
in Thailand means most drugs of any commercial importance
will acquire patent protection (and therefore already have
market exclusivity) and data exclusivity will increasingly
become less crucial.
Compulsory licensing
--------------------
¶21. (U) FTA critics also point to restrictions in previous
FTAs on the terms under which a country may issue a
compulsory license. Under certain conditions WTO rules allow
local manufacturers to produce a patented medicine without
license from the original manufacturer. These conditions
include the existence of a public health emergency for which
the medicine is required.
¶22. (U) Despite frequent urgings by NGO activists and MoPH,
the RTG has yet to issue a compulsory license for any drug.
Activists readily attribute this to USG pressure and RTG
unwillingness to damage the bilateral relationship with the
U.S. However, an industry analyst suggested that GPO
realized it simply would not be cost-effective to produce
some generics under a compulsory license, no matter the need.
The costs involved in producing a generic copy, including
the cost of importing ingredients, research and development,
and license fees to the patent holder could surpass the cost
of simply purchasing the product.
¶23. (SBU) NGO activists frequently point to the
extraordinary high prices of patented ARVs, but the potential
for greatly reduced generic prices may in fact be low. FTA
critics most often cite two patented drugs, efavirenz by
Merck, Inc., and Kaletra by Abbott Laboratories, as essential
ARVs with prices far beyond the means of the average HIV/AIDS
patient, and call for compulsory licenses for local
production in Thailand. However, Merck representatives said
that they sold efavirenz in Thailand at a no-profit price in
recognition of Thailand,s AIDS situation and developing
nation status (though MoPH complains it is chronically in
short supply). As well, a survey on ARV pricing by Medecins
Sans Frontieres showed that the 600 mg tablet of efavirenz
was already being sold in Thailand at the same price as the
cheapest generic version in India. It is unlikely that GPO
could beat Indian manufacturers on price.
¶24. (SBU) Kaletra, the second-line ARV which is the other
frequent target, is sold for $300 a month, ten times the
price of generic first-line ARV GPO-vir, but a generic copy
would also likely be expensive, at least in the short run.
Brazilian generic manufacturers recently claimed that if the
patent were broken in Brazil they could manufacture Kaletra
for approximately USD 1000 per year, still several times more
expensive than GPO-vir.
¶25. (U) At present the likelihood for the RTG to issue a
compulsory license on an ARV is low. There are relatively
fewer HIV patients who require second-line ARVs in Thailand,
and in the short run economies of scale are perhaps too small
to warrant local production. However, the MoPH's program to
provide ARVs to significantly larger number of HIV positive
patients promises to slow the fatality rate from AIDS and
increase the overall number of HIV positive patients. As
more of these patients move to expensive second-line ARV
regimens the additional costs may fuel renewed calls for
compulsory licenses for these ARVs.
Can they make the generics?
---------------------------
¶26. (U) The Government Pharmaceutical Organization takes
the lead on development of generic copies of innovative
drugs, though they also perform their own original research
and in fact hold a number of patents. GPO manufactures
approximately 300 pharmaceutical products, including a number
of generic ARVs. GPO's facilities are generally highly
regarded and in a meeting with Econoff, R&D Director Ms.
Pisamorn Klinsuwan insisted that GPO had the capability to
produce some of the most complicated drugs on the market,
including second-line ARVs such as Kaletra were they given
the opportunity.
¶27. (SBU) GPO had their eye on producing other patented
drugs including blockbuster anti-cholesterol medicine
Lipitor, the top-selling drug in Thailand. Pisamorn claimed
GPO could produce the drug at half the cost of its current
retail price, but admitted that estimate did not include R&D
costs. R&D was tallied in a separate budget and not factored
into overall production costs.
¶28. (SBU) Although GPO produces generic copies at
substantially reduced prices from original versions, the
state-owned firm still faces many of the same market
constraints as a private firm. GPO's R&D director told
Econoff that GPO was researching all available ARVs for
future production, but decisions to produce other drugs were
dependent on local conditions. GPO took into account the
need for a new drug when deciding whether to produce a
generic copy, but like other pharmaceutical companies had to
examine the size of the market and whether it would be worth
the investment to produce a generic copy. Absence of a
patent on an original drug was insufficient criteria to
produce a generic. Although GPO is state-owned, it receives
no budget support from the RTG and is expected to turn a
profit both to expand operations and to provide budgetary
support to the RTG.
¶29. (SBU) GPO is preparing to produce the anti-viral
medicine Tamiflu, considered to be effective in battling
various strains of avian influenza. The original
manufacturer, Roche Holding AG, confirmed to the RTG that
Tamiflu was not patented in Thailand and that GPO was not
restricted from producing the drug nor obligated to pay a
licensing fee. GPO is acquiring precursor ingredients from
Indian pharmaceutical companies and has claimed it can
produce enough Tamiflu for 5000 patients within a year.
Tariff issue
------------
¶30. (U) Pharmaceutical reps in Thailand often take issue
with RTG complaints about the need for lower drug prices,
noting that Thailand maintains a ten percent tariff on
pharmaceutical products, with exceptions for medicines for
HIV/AIDS, malaria, thallassaemia and vaccines, which are
zero-rated. Zero-rated medicines make up less than ten
percent of the value of Thai pharmaceutical imports. A
successful conclusion to the FTA and a reduction in tariffs
could produce a drop in overall pharmaceutical costs.
Taking the long view
--------------------
¶31. (U) Although little immediate effect on pharmaceutical
costs would appear to be likely after implementation of an
FTA with the U.S., Thais are concerned about future drugs
entering the pipeline. The HIV/AIDS crisis is diminishing
thanks to greatly improved treatment and access to ARVs, but
restricted access to future generations of ARVs could set
back the progress made to date. Thais are concerned as well
that a future vaccine or treatment for avian flu might be
marketed at prices beyond their means to prevent an epidemic.
¶32. (U) Analysts do not foresee future difficulties with
unreasonable delays in patent and marketing approval
processes and resulting lengthening of a drug,s patent term.
The importance of ARVs and other life-saving medicines
virtually ensures that the RTG would quickly approve patents
and marketing for any future treatments or cures. In
addition, important drugs of this nature would almost
certainly be patented (if a decision were not made to license
them locally), and put on the market relatively quickly, and
therefore data exclusivity would be unlikely to come into
play. Industry observers agree that despite less than rapid
service for the typical patent at the Thai Patent Office,
additional resources should ensure that few new patent
applications face any unreasonable delays.
¶33. (U) Despite predictions of skyrocketing drug prices by
anti-FTA activists, the long-term outlook in the
pharmaceutical industry has not changed. Company reps in
Bangkok did not appear to be altering business models in
Thailand in anticipation of a U.S.-Thai FTA and did not
expect any significant increases in revenue after its
passage. Several company reps were unaware an FTA might have
provisions that would affect their products. One analyst
explained that the industry was supporting the FTA's patent
provisions primarily to help set a precedent for future FTAs
in more important markets.
¶34. (U) Comment: The debate over access to medicines and
FTAs presents a dichotomy of goals: access to cheap and
effective medicines for patients who need them now, but
incentives for development of innovative drugs for the future
as well. The hard truth is that without economic incentives
to manufacture an innovative new drug, it won,t be made; if
no market exists in Thailand for a new drug to be sold
profitably, it won,t be marketed, even by Thai generic
manufacturers.
¶35. (U) Inevitably, some drugs would be affected by an FTA
and raise overall pharmaceutical costs, though the increased
costs of individual drugs could be offset by tariff
reductions on pharmaceutical imports overall. Thailand has
an advantage in that it has a sizable market for new
medicines and can promote competition, and has also developed
a strong generic industry to compete with off-patent drugs.
Its generic industry's ability to copy most any drug also
backs up the occasional threat to issue a compulsory license
and helps persuade companies to keep prices lower than they
might otherwise. However, Thailand's program to provide HIV
medicines to more patients portends a future of skyrocketing
health care costs as HIV-positive patients live longer and
move on to expensive second-line regimens. The threat of a
compulsory license may one day cease to be only a threat.
End comment.
¶36. (U) Embassy expects an uphill battle against organized
opposition to the FTA and overcoming fears among Thais of
skyrocketing drug prices and a widening HIV/AIDS crisis. As
part of an overall outreach effort, Embassy suggests use of
the following talking points regarding pharmaceutical costs
and the FTA:
-- No provision exists in the IPR chapter of the U.S.-Thai
FTA that would encourage pharmaceutical companies to raise
prices for their products. On the contrary, a reduction in
the ten percent tariff on most pharmaceutical imports could
reduce prices for many drugs in Thailand.
-- Few essential drugs would likely be granted additional
market exclusivity by an FTA. We know of no anti-retroviral
medicines to treat HIV patients that would be affected.
-- Additional resources from the RTG to improve patent and
marketing approval procedures would go far to removing the
potential for patent term extensions on individual drugs, and
speed essential drugs to patients as well.
BOYCE